Figure 1.
Specific enrichment of macrophages in bone-metastatic PC is associated with patient survival. (A) Macrophages are significantly enriched in bone metastasis compared with PC metastasis from other organs. Top: Box plot showing quantification of xCell enrichment score of different stromal cell types in PC metastases in different organs. Bottom: Illustration showing significance of the comparisons: ↑, significantly higher in bone metastasis; —, not significantly different; ×, specific cell type is not present; N.S.E., not significantly estimated with xCell. Significant means P < 0.05 with ANOVA test. (B) Macrophages are significantly enriched in bone metastasis compared with PC primary tumor. Top: Box plot showing quantification of xCell enrichment score of different stromal cell types in PC bone metastasis versus primary PC. Bottom: Illustration showing significance of the comparisons: ↑, significantly higher in bone metastasis; —, not significantly different; ×, specific cell type is not present; N.S.E., not significantly estimated with xCell. Significant means P < 0.05 with two-tailed unpaired Student’s t test. (C) Estimation of macrophage abundance in patient PC bone metastasis and metastases from other organs in indicated datasets. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. ANOVA was used. (D) Estimation of macrophage abundance in patient PC bone metastasis and primary PC in Gene Expression Omnibus dataset GSE32269. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. Two-tailed unpaired Student’s t test was used. (E) Overall survival of macrophage abundance with median as cut-off in all patients (left), patients without bone metastasis (middle), and patients with bone metastasis (right) in the SU2C dataset. *, P < 0.05; ns, not significant. P value was calculated using the Mantel–Cox test.

Specific enrichment of macrophages in bone-metastatic PC is associated with patient survival. (A) Macrophages are significantly enriched in bone metastasis compared with PC metastasis from other organs. Top: Box plot showing quantification of xCell enrichment score of different stromal cell types in PC metastases in different organs. Bottom: Illustration showing significance of the comparisons: ↑, significantly higher in bone metastasis; —, not significantly different; ×, specific cell type is not present; N.S.E., not significantly estimated with xCell. Significant means P < 0.05 with ANOVA test. (B) Macrophages are significantly enriched in bone metastasis compared with PC primary tumor. Top: Box plot showing quantification of xCell enrichment score of different stromal cell types in PC bone metastasis versus primary PC. Bottom: Illustration showing significance of the comparisons: ↑, significantly higher in bone metastasis; —, not significantly different; ×, specific cell type is not present; N.S.E., not significantly estimated with xCell. Significant means P < 0.05 with two-tailed unpaired Student’s t test. (C) Estimation of macrophage abundance in patient PC bone metastasis and metastases from other organs in indicated datasets. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. ANOVA was used. (D) Estimation of macrophage abundance in patient PC bone metastasis and primary PC in Gene Expression Omnibus dataset GSE32269. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. Two-tailed unpaired Student’s t test was used. (E) Overall survival of macrophage abundance with median as cut-off in all patients (left), patients without bone metastasis (middle), and patients with bone metastasis (right) in the SU2C dataset. *, P < 0.05; ns, not significant. P value was calculated using the Mantel–Cox test.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal